These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34769137)

  • 1. PR-619, a General Inhibitor of Deubiquitylating Enzymes, Diminishes Cisplatin Resistance in Urothelial Carcinoma Cells through the Suppression of c-Myc: An In Vitro and In Vivo Study.
    Hsu FS; Lin WC; Kuo KL; Chiu YL; Hsu CH; Liao SM; Dong JR; Liu SH; Chang SC; Yang SP; Chen YT; Chang RJ; Huang KH
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study.
    Kuo KL; Liu SH; Lin WC; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
    Cells; 2019 Oct; 8(10):. PubMed ID: 31627336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study.
    Kuo KL; Liu SH; Lin WC; Hsu FS; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
    Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
    J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
    Chow PM; Chang YW; Kuo KL; Lin WC; Liu SH; Huang KH
    Cancer Lett; 2021 Jun; 507():70-79. PubMed ID: 33741425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
    Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
    Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer.
    Lin W; Sun J; Sadahira T; Xu N; Wada K; Liu C; Araki M; Xu A; Watanabe M; Nasu Y; Huang P
    Int J Biol Sci; 2021; 17(12):3255-3267. PubMed ID: 34421363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
    Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
    Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
    Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
    Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
    Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
    Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
    Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.
    Li Y; Zu X; Hu X; Wang L; He W
    Med Sci Monit; 2019 Nov; 25():8928-8939. PubMed ID: 31761897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
    Ma Y; Yu WD; Trump DL; Johnson CS
    Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering the Molecular Mechanism Underlying the Inhibitory Efficacy of Taiwanese Local Pomegranate Peels against Urinary Bladder Urothelial Carcinoma.
    Chang CP; Chan YY; Li CF; Chien LH; Lee ST; Wu TF
    Nutrients; 2018 Apr; 10(5):. PubMed ID: 29702555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
    Woolbright BL; Choudhary D; Mikhalyuk A; Trammel C; Shanmugam S; Abbott E; Pilbeam CC; Taylor JA
    Mol Cancer Ther; 2018 Sep; 17(9):2004-2012. PubMed ID: 29907593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR34a/GOLPH3 Axis abrogates Urothelial Bladder Cancer Chemoresistance via Reduced Cancer Stemness.
    Zhang Q; Zhuang J; Deng Y; Yang L; Cao W; Chen W; Lin T; Lv X; Yu H; Xue Y; Guo H
    Theranostics; 2017; 7(19):4777-4790. PubMed ID: 29187903
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.
    Schlütermann D; Skowron MA; Berleth N; Böhler P; Deitersen J; Stuhldreier F; Wallot-Hieke N; Wu W; Peter C; Hoffmann MJ; Niegisch G; Stork B
    Urol Oncol; 2018 Apr; 36(4):160.e1-160.e13. PubMed ID: 29276062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.
    Skowron MA; Melnikova M; van Roermund JGH; Romano A; Albers P; Thomale J; Schulz WA; Niegisch G; Hoffmann MJ
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The UCHL5 inhibitor b-AP15 overcomes cisplatin resistance via suppression of cancer stemness in urothelial carcinoma.
    Chow PM; Dong JR; Chang YW; Kuo KL; Lin WC; Liu SH; Huang KH
    Mol Ther Oncolytics; 2022 Sep; 26():387-398. PubMed ID: 36090476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
    Hsu FS; Wu JT; Lin JY; Yang SP; Kuo KL; Lin WC; Shi CS; Chow PM; Liao SM; Pan CI; Hong JY; Chang HC; Huang KH
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.